HeraMED Ltd. (AU:HMD) has released an update.
HeraMED Limited has announced the appointment of Anoushka Gungadin as a director, with an initial interest of 850,000 options expiring in 2027 at an exercise price of $0.1358. These options were issued when Gungadin joined HeraMED as the director of strategic partnerships for Australia and New Zealand in August 2022. No further details on director’s interests or contracts were disclosed.
For further insights into AU:HMD stock, check out TipRanks’ Stock Analysis page.
